BNC Korea Co, Ltd Logo

BNC Korea Co, Ltd

Develops hyaluronic acid-based dermal fillers and botulinum toxin injectables.

256840 | KO

Overview

Corporate Details

ISIN(s):
KR7256840000
LEI:
Country:
South Korea
Address:
대구광역시 달서구 성서공단로11길 62 대구테크노파크 벤처공장 1호관 405호(사무실),502호, 503호, 206호, 대구광역시

Description

BNC Korea Co., Ltd. is a biomedical company established in 2007 that engages in the research, development, production, and sale of medical devices, pharmaceuticals, and biologicals. The company specializes in products derived from biomaterials, with a particular focus on hyaluronic acid. Its core product portfolio includes hyaluronic acid-based dermal fillers and botulinum toxin injectables for the medical aesthetics market. BNC Korea operates a GMP-certified facility for manufacturing cutting-edge drug substances and specialty medicines, aiming to develop strategic application products for next-generation bio markets.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-16 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.3 KB
2025-12-16 00:00
현금ㆍ현물배당을위한주주명부폐쇄(기준일)결정
Korean 6.0 KB
2025-08-29 00:00
기타경영사항(자율공시) (의약품 회수·폐기 및 잠정 제조중지 등 명령 취소 소송 1심 판결)
Korean 10.7 KB
2025-08-26 00:00
투자판단관련주요경영사항 (CL-N, N 중국 국가약품감독관리국(NMPA) 품목허가 획득)
Korean 12.6 KB
2025-08-14 00:00
[기재정정]사업보고서 (2024.12)
Korean 2.1 MB
2025-08-14 00:00
반기보고서 (2025.06)
Korean 1.6 MB
2025-07-21 00:00
투자판단관련주요경영사항 (Cutegel 중국 국가약품감독관리국(NMPA) 품목허가 획득)
Korean 8.4 KB
2025-07-08 00:00
주식등의대량보유상황보고서(일반)
Korean 107.0 KB
2025-05-30 00:00
기타경영사항(자율공시)
Korean 6.4 KB
2025-05-15 00:00
분기보고서 (2025.03)
Korean 1.5 MB
2025-04-29 00:00
연결재무제표기준영업(잠정)실적(공정공시)
Korean 16.5 KB
2025-04-08 00:00
주식등의대량보유상황보고서(일반)
Korean 107.2 KB
2025-03-31 00:00
정기주주총회결과
Korean 19.9 KB
2025-03-21 00:00
감사보고서제출
Korean 25.3 KB
2025-03-21 00:00
사업보고서 (2024.12)
Korean 2.1 MB

Automate Your Workflow. Get a real-time feed of all BNC Korea Co, Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BNC Korea Co, Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BNC Korea Co, Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.